AI Helped Develop a Drug in a Record 18 Months

Artificial intelligence (AI) has enabled the development of a new drug for a deadly lung disease in record time. Read more about how generative AI is changing the game for drug development, from research to clinical trials.

Share
AI Helped Develop a Drug in a Record 18 Months

For the first time, a drug developed with the help of artificial intelligence (AI) has reached Phase 2 clinical trials in both China and the United States. This drug, developed to combat an aggressive and often fatal lung disease, marks a milestone in the pharmaceutical industry. Insilico Medicine, a company specializing in AI-driven drug discovery, highlights this as proof of generative AI technology's potential to revolutionize the industry.

From Decades of Research to Rapid Development

Insilico Medicine's founder and CEO, Alex Zhavoronkov, has been exploring the applications of generative AI in biomedical research for over a decade. By integrating AI, robotics, and aging research, the company aims to find comprehensive treatments for complex diseases such as Alzheimer's and Parkinson's. Since 2014, Insilico has used AI to understand human aging and track health throughout life, with the goal of not just slowing diseases but preventing them entirely.

Generative AI Accelerates Drug Development

In a groundbreaking study, researchers used generative AI to identify and inhibit targets for idiopathic pulmonary fibrosis (IPF) – a disease that causes chronic scarring of lung tissue and difficulty breathing. With over 5 million people affected worldwide, and a median survival of only two to three years for untreated patients, this development represents a significant breakthrough. By shortening the traditional drug development timeline, which often spans a decade, to just 18 months from target discovery to preclinical candidate, Insilico demonstrates how AI can streamline the process from the lab to clinical trials.

AI at the Forefront of Drug Research

The research, published in Nature Biotechnology, used an AI platform to first identify a target for fibrosis – a condition related to aging and chronic inflammation. A generative chemistry engine then generated approximately 80 small-molecule candidates, resulting in the inhibitor INS018_055, which showed promising properties and anti-fibrotic activity.

Clinical Trials and the Future of AI in Drug Development

The ongoing Phase 2a clinical trials of INS018_055 in China and the US, with 60 patients in each study, will evaluate the drug's safety, tolerability, and pharmacokinetics, as well as its preliminary effect on lung function in IPF patients. This development highlights AI's role in speeding up the early stages of drug development and its potential to transform the discovery and development of new treatments.

Source - Link